March 22, 2018 05:28 AM EDT
R&D

Cash­ing in on PhII tri­al suc­cess, Are­na to raise $353M to fu­el PhI­II etrasi­mod/ra­linepag tri­als

Brittany Meiling

Tak­ing ad­van­tage of its stock’s hot po­si­tion this week, Are­na $AR­NA is fol­low­ing its promis­ing Phase II da­ta with a pub­lic of­fer­ing that should bring …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

A service from the Financial Times